Literature DB >> 22372347

Hemolysis is a major cause of variability in insulin measurement during oral glucose tolerance test in children.

Giorgio Bellomo1, Maria Giovanna Sulas, Elisabetta Mairate, Maria Beatrice Bardone, Roberta Rolla.   

Abstract

BACKGROUND: The oral glucose tolerance test (OGTT) is widely employed to evaluate insulin resistance in children with growth hormone deficiency. Due to the difficulty in blood sampling, hemolysis is a frequent pre-analytic interference. The present study was performed to characterize the effects of hemolysis on insulin assays, in order to assess the need to generate automatic hemolysis reports and/or to reject hemolyzed samples.
METHODS: Insulin plasma levels were measured using a Siemens ADVIA Centaur on samples obtained from children with suspected GH deficiency at risk for insulin resistance during OGTT.
RESULTS: The presence of hemolysis (with a concentration of free hemoglobin above 75 mg/dL) promotes a dose- and time-dependent decrease in immunoreactive insulin at any time-point evaluated during OGTT. As a consequence, the variability of insulin is particularly high (often exceeding 100% of the mean value) as compared to that of glucose. This variability is markedly reduced after removal of the hemolyzed samples.
CONCLUSIONS: When hemolysis is not taken into account a misinterpretation of insulin secretion pattern can occur. It is therefore imperative to: (i) analyze blood samples immediately after sampling, (ii) reject samples with a concentration of free hemoglobin equal to or above 125 mg/dL and (iii) always report the possible interference.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22372347

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  7 in total

1.  A guide for measurement of circulating metabolic hormones in rodents: Pitfalls during the pre-analytical phase.

Authors:  Maximilian Bielohuby; Sarah Popp; Martin Bidlingmaier
Journal:  Mol Metab       Date:  2012-08-09       Impact factor: 7.422

2.  Hemolysis Affects C-Peptide Immunoassay.

Authors:  Zhi-Qi Wu; Ju Lu; Hua-Guo Xu
Journal:  J Clin Lab Anal       Date:  2016-05-26       Impact factor: 2.352

3.  Individualized correction of insulin measurement in hemolyzed serum samples.

Authors:  Zhi-Qi Wu; Ju Lu; Huanhuan Chen; Wensen Chen; Hua-Guo Xu
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

4.  Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome.

Authors:  C S Filgueira; E Nicolov; R L Hood; A Ballerini; J Garcia-Huidobro; J Z Lin; D Fraga; P Webb; O M Sabek; A O Gaber; K J Phillips; A Grattoni
Journal:  Int J Obes (Lond)       Date:  2016-07-27       Impact factor: 5.095

Review 5.  Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia.

Authors:  Diva D De León; Charles A Stanley
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-07-09       Impact factor: 4.690

6.  Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies.

Authors:  North Foulon; Elisha Goonatilleke; Michael J MacCoss; Michelle A Emrick; Andrew N Hoofnagle
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2022-06-10

7.  Bacitracin attenuates haemolysis-induced insulin degradation during insulin sensitivity testing: Repurposing an old drug for use in metabolic research.

Authors:  Andrew P Demidowich; Jordan A Levine; Sheila M Brady; Cheryl D Johnson; Steven J Soldin; Jack A Yanovski
Journal:  Diabetes Obes Metab       Date:  2020-04-20       Impact factor: 6.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.